NON-SMALL CELL LUNG CANCER STAGE III

This phase 2 trial is testing the drug sotorasib (AMG510) in people with stage III non-small cell lung cancer that has a specific genetic change called KRAS G12C. Participants cannot receive standard chemo-radiation due to medical reasons. The study aims to see if sotorasib can h…

This study uses a blood test to detect tiny amounts of cancer DNA left after standard treatment for early-stage non-small cell lung cancer. People whose blood shows this leftover cancer are at higher risk of the cancer coming back. The study tests whether the drug durvalumab can …

This study tests a new approach for people with advanced lung cancer whose disease got worse after initial treatment. It combines an injected virus (Olvi-Vec) that targets cancer cells, followed by chemotherapy and an immunotherapy drug, and compares it to standard chemotherapy a…

This study tests whether giving chemotherapy plus an immunotherapy drug (cemiplimab) before surgery can help people with stage 3 lung cancer that has spread to certain lymph nodes. About 21 adults will receive four cycles of the combination, then undergo surgery to remove the can…

This study looks at whether pulmonary rehabilitation—a program of exercise and breathing techniques—can improve breathing, fatigue, and quality of life for people with advanced non-small cell lung cancer. Half of the 85 participants will do an 8-week rehab program, while the othe…

This study tests whether a newer, MRI-guided radiation method (MRgART) is gentler on the heart than standard radiation (LINAC) for people with lung, esophageal, or other chest cancers. About 60 adults will receive radiation and have their heart function checked via MRI and blood …

This study observes 50 people with stage III non-small cell lung cancer who have already received chemotherapy with radiation and are about to start immunotherapy. Researchers will look at medical records to see how the immune system responds and how long patients live without th…